NR1H4 and metabolic disease: Indeed, pharmacological activation of FXR and FGF21 receptors has been demonstrated to enhance thermogenesis and WAT browning in animal models, and several FXR modulators and FGF21 analogues are currently under clinical evaluation for the treatment of metabolic diseases in humans85,86.